|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for TRAF2 |
 Gene summary |
| Basic gene Info. | Gene symbol | TRAF2 |
| Gene name | TNF receptor-associated factor 2 | |
| Synonyms | MGC:45012|TRAP|TRAP3 | |
| Cytomap | UCSC genome browser: 9q34 | |
| Type of gene | protein-coding | |
| RefGenes | NM_021138.3, | |
| Description | E3 ubiquitin-protein ligase TRAF2tumor necrosis factor type 2 receptor associated protein 3tumor necrosis factor type 2 receptor-associated protein 3 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601895 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000127191 | ||
| HPRD : 03538 | ||
| Vega : OTTHUMG00000020952 | ||
| Protein | UniProt: Q12933 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_TRAF2 | |
| BioGPS: 7186 | ||
| Pathway | NCI Pathway Interaction Database: TRAF2 | |
| KEGG: TRAF2 | ||
| REACTOME: TRAF2 | ||
| Pathway Commons: TRAF2 | ||
| Context | iHOP: TRAF2 | |
| ligand binding site mutation search in PubMed: TRAF2 | ||
| UCL Cancer Institute: TRAF2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 11907583 | GO:0042981 | regulation of apoptotic process | 11907583 | GO:0043507 | positive regulation of JUN kinase activity | 11907583 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 11279055 | GO:0051865 | protein autoubiquitination | 20577214 | GO:0070534 | protein K63-linked ubiquitination | 15258597 |
| Top |
| Ligand binding site mutations for TRAF2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C112 | W114R | COAD | 1 | F410 | S408F | SKCM | 1 | A466 | A466T | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for TRAF2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A466 | A466T | -1.1626675 | C112 | W114R | -0.95825694 | F410 | S408F | -0.7184647 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for TRAF2 from PDB |
| Top |
| Differential gene expression and gene-gene network for TRAF2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for TRAF2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for TRAF2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of TRAF2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 3knv | A | C112 | III | Peptide ligand (PRO,PHE,SER,LYS,GLU,GLU,CYS) | 1ca9 | A | F410 A466 | III | Peptide ligand (GLY,GLN,VAL,PRO,PHE,SER,LYS,GLU,GLU,CYS) | 1ca9 | B | F410 A466 | III | Peptide ligand (ACE,PRO,GLN,GLN,ALA,THR,ASP,ASP) | 1czy | A | F410 A466 | III | Peptide ligand (PRO,GLN,GLN,ALA,THR,ASP,ASP) | 1czy | C | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,LEU,HIS) | 1czz | A | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,LEU,HIS,GLY,CYS) | 1czz | B | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | A | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | B | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | C | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | D | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | E | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | F | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | G | F410 A466 | III | Peptide ligand (ACE,PRO,VAL,GLN,GLU,THR,NH2) | 1d00 | H | F410 A466 | III | Peptide ligand (ACE,MET,LEU,SER,VAL,GLU,GLU,GLU,GLY) | 1d01 | D | F410 A466 | III | Peptide ligand (ACE,MET,LEU,SER,VAL,GLU,GLU,GLU,GLY) | 1d01 | E | F410 A466 | III | Peptide ligand (ACE,MET,LEU,SER,VAL,GLU,GLU,GLU,GLY) | 1d01 | F | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | A | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | B | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | C | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | D | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | E | F410 A466 | III | Peptide ligand (ACE,PRO,ILE,GLN,GLU,GLU) | 1d0a | F | F410 A466 | III | Peptide ligand (ALA,ALA,GLN,GLU,GLU) | 1d0j | A | F410 A466 | III | Peptide ligand (ALA,ALA,GLN,GLU,GLU) | 1d0j | C | F410 A466 | III | Peptide ligand (ACE,GLY,ALA,ALA,GLN,GLU,GLU) | 1d0j | D | F410 A466 | III | Peptide ligand (GLY,ALA,ALA,GLN,GLU,GLU) | 1d0j | E | F410 A466 | III | Peptide ligand (ALA,ALA,GLN,GLU,GLU) | 1d0j | F | F410 A466 | III | Peptide ligand (ACE,TYR,PRO,ILE,GLN,GLU,THR) | 1qsc | A | F410 A466 | III | Peptide ligand (ACE,TYR,PRO,ILE,GLN,GLU,THR) | 1qsc | B | F410 A466 | III | Peptide ligand (ACE,TYR,PRO,ILE,GLN,GLU,THR) | 1qsc | C | F410 A466 |
| Top |
| Conservation information for LBS of TRAF2 |
| Multiple alignments for Q12933 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |